{"id":34879,"date":"2024-09-17T00:28:28","date_gmt":"2024-09-17T00:28:28","guid":{"rendered":"https:\/\/beyondtype2.org\/el-sistema-de-monitoreo-continuo-de-glucosa-eversense-365-recibe-la-aprobacion-de-la-fda-el-primer-cgm-de-un-ano\/"},"modified":"2024-12-12T18:59:13","modified_gmt":"2024-12-12T18:59:13","slug":"fda-eversense-365","status":"publish","type":"resources","link":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/","title":{"rendered":"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o"},"content":{"rendered":"<p>El 17 de septiembre de 2024, <a href=\"https:\/\/www.senseonics.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Senseonics Holdings, Inc.<\/a> , en colaboraci&oacute;n con <a href=\"https:\/\/www.ascensia.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Ascensia Diabetes Care,<\/a> anunci&oacute; que la Administraci&oacute;n de Alimentos y Medicamentos de los EE. UU. ( <em>FDA<\/em> ) ha aprobado el sistema de monitoreo continuo de glucosa Eversense 365. Este innovador <a href=\"https:\/\/beyondtype1.org\/es\/tabla-mcg-beyond-type-1\/\">MCG<\/a> es el primero en el mundo en ofrecer un sensor que dura un a&ntilde;o completo, lo que marca un paso revolucionario en el manejo de la diabetes. El sistema de monitoreo continuo de glucosa Eversense 365 ( <em>Eversense 365<\/em> ) est&aacute; dise&ntilde;ado para adultos con diabetes <a href=\"https:\/\/beyondtype1.org\/es\/que-es-la-diabetes-tipo-1\/\">tipo 1<\/a> y <a href=\"https:\/\/beyondtype1.org\/es\/que-es-la-diabetes-tipo-2-2\/\">tipo 2,<\/a> brind&aacute;ndoles una opci&oacute;n m&aacute;s conveniente y duradera. A diferencia de los CGM tradicionales, que requieren cambios frecuentes de sensor cada 10 a 14 d&iacute;as, Eversense 365 solo requiere una inserci&oacute;n de sensor por a&ntilde;o. Esta caracter&iacute;stica minimiza las interrupciones y simplifica el manejo de la diabetes, lo que permite a los usuarios concentrarse m&aacute;s en vivir la vida en lugar de controlar su condici&oacute;n. &ldquo;La aprobaci&oacute;n de Eversense 365 representa un gran avance en la innovaci&oacute;n de los sistemas de monitorizaci&oacute;n continua de la glucosa&rdquo;, afirm&oacute; el Dr. Tim Goodnow, presidente y director ejecutivo de Senseonics. &ldquo;La ampliaci&oacute;n de la vida &uacute;til del sensor a un a&ntilde;o completo, junto con una conectividad perfecta del dispositivo y un alto nivel de precisi&oacute;n, brinda libertad y tranquilidad a los pacientes que viven con diabetes&rdquo;.<\/p>\n<h3>Principales ventajas de Eversense 365<\/h3>\n<ul>\n<li><strong><em>CGM de mayor duraci&oacute;n<\/em><\/strong> : con un sensor de 365 d&iacute;as, los usuarios solo necesitan insertar un sensor por a&ntilde;o, lo que reduce las molestias de los cambios frecuentes.<\/li>\n<li><strong><em>Mayor confiabilidad<\/em><\/strong> : el sistema reduce el riesgo de interrupciones de datos comunes con los CGM de corto plazo.<\/li>\n<li><strong><em>Alertas confiables<\/em><\/strong> : precisi&oacute;n excepcional con casi ninguna falsa alarma, especialmente durante la noche.<\/li>\n<li><strong><em>Comodidad mejorada<\/em><\/strong> : el adhesivo suave est&aacute; dise&ntilde;ado para minimizar las reacciones de la piel, mientras que el transmisor extra&iacute;ble ofrece m&aacute;s flexibilidad y libertad.<\/li>\n<li><strong><em>Discreto y conveniente<\/em><\/strong> : las alertas de vibraci&oacute;n notifican a los usuarios incluso cuando su tel&eacute;fono est&aacute; fuera de su alcance.<\/li>\n<\/ul>\n<h3>Disponibilidad comercial e integraci&oacute;n futura<\/h3>\n<p>El lanzamiento de Eversense 365 est&aacute; previsto para el cuarto trimestre de 2024, y se est&aacute;n realizando esfuerzos para garantizar la cobertura del seguro para una amplia disponibilidad. Adem&aacute;s, el sistema ha sido aprobado como un CGM integrado ( <em>iCGM<\/em> ), lo que significa que puede funcionar con bombas de insulina como parte de los sistemas de administraci&oacute;n automatizada de insulina ( <em>AID<\/em> ) . Ascensia y Senseonics est&aacute;n trabajando en asociaciones para ampliar estas capacidades de integraci&oacute;n, mejorando a&uacute;n m&aacute;s la atenci&oacute;n de la diabetes. Para obtener m&aacute;s informaci&oacute;n sobre Eversense 365 y su disponibilidad, visite <a href=\"https:\/\/www.eversensecgm.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">www.eversensecgm.com<\/a> .<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>El 17 de septiembre de 2024, Senseonics Holdings, Inc. , en colaboraci&oacute;n con Ascensia Diabetes Care, anunci&oacute; que la Administraci&oacute;n de Alimentos y Medicamentos de los EE. UU. ( FDA ) ha aprobado el sistema de monitoreo continuo de glucosa Eversense 365. Este innovador MCG es el primero en el mundo en ofrecer un sensor [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":34653,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-34879","resources","type-resources","status-publish","has-post-thumbnail","hentry","content-categories-noticias","topics-tecnologia-y-equipamiento","diabetes-types-tipo-1","tags-news-es","tags-noticias"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1<\/title>\n<meta name=\"description\" content=\"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1\" \/>\n<meta property=\"og:description\" content=\"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 1\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beyondtype1\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-12T18:59:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"430\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BeyondType1\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/\",\"url\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/\",\"name\":\"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1\",\"isPartOf\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png\",\"datePublished\":\"2024-09-17T00:28:28+00:00\",\"dateModified\":\"2024-12-12T18:59:13+00:00\",\"description\":\"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png\",\"width\":1200,\"height\":430,\"caption\":\"FDA Clears Eversense 365: First One-Year CGM Sensor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/beyondtype1.org\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"name\":\"Beyond Type 1\",\"description\":\"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.\",\"publisher\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/beyondtype1.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\",\"name\":\"Beyond Type 1\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"width\":56,\"height\":56,\"caption\":\"Beyond Type 1\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/beyondtype1\",\"https:\/\/x.com\/BeyondType1\",\"http:\/\/instagram.com\/BeyondType1\/\",\"https:\/\/www.youtube.com\/c\/BeyondType1\",\"https:\/\/www.tiktok.com\/@beyondtype1\",\"https:\/\/www.linkedin.com\/company\/beyond-type1\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1","description":"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/","og_locale":"es_ES","og_type":"article","og_title":"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1","og_description":"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.","og_url":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/","og_site_name":"Beyond Type 1","article_publisher":"https:\/\/www.facebook.com\/beyondtype1","article_modified_time":"2024-12-12T18:59:13+00:00","og_image":[{"width":1200,"height":430,"url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BeyondType1","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/","url":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/","name":"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o | Beyond Type 1","isPartOf":{"@id":"https:\/\/beyondtype1.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage"},"thumbnailUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png","datePublished":"2024-09-17T00:28:28+00:00","dateModified":"2024-12-12T18:59:13+00:00","description":"La FDA aprueba el sistema de monitoreo continuo de glucosa Eversense 365: el primer CGM de un a\u00f1o del mundo para personas con diabetes.","breadcrumb":{"@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtype1.org\/es\/fda-eversense-365\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#primaryimage","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-SAVING-OFFER-FOR-THE-EVERSENSE-EG3-HEADER-1980x709-1-1200x430-1.png","width":1200,"height":430,"caption":"FDA Clears Eversense 365: First One-Year CGM Sensor"},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtype1.org\/es\/fda-eversense-365\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtype1.org\/es\/"},{"@type":"ListItem","position":2,"name":"El sistema de monitoreo continuo de glucosa Eversense 365 recibe la aprobaci\u00f3n de la FDA: el primer CGM de un a\u00f1o"}]},{"@type":"WebSite","@id":"https:\/\/beyondtype1.org\/es\/#website","url":"https:\/\/beyondtype1.org\/es\/","name":"Beyond Type 1","description":"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.","publisher":{"@id":"https:\/\/beyondtype1.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtype1.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/beyondtype1.org\/es\/#organization","name":"Beyond Type 1","url":"https:\/\/beyondtype1.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","width":56,"height":56,"caption":"Beyond Type 1"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beyondtype1","https:\/\/x.com\/BeyondType1","http:\/\/instagram.com\/BeyondType1\/","https:\/\/www.youtube.com\/c\/BeyondType1","https:\/\/www.tiktok.com\/@beyondtype1","https:\/\/www.linkedin.com\/company\/beyond-type1\/"]}]}},"_links":{"self":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/34879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/types\/resources"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/comments?post=34879"}],"version-history":[{"count":0,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/34879\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media\/34653"}],"wp:attachment":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media?parent=34879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}